Professor Klastersky has been Head of the Department of Medicine at the Institut Jules Bordet in Brussels and Professor of Medicine, Medical Oncology and Physical Diagnosis at the Université Libre de Bruxelles since 1977.

He retired from these positions in 2005. Currently, he is the Coordinator of the “Programme des Soins Oncologiques” for the nine IRIS (Interhospitalière Régionale des Infrastructures de Soins) hospitals in Brussels and Consultant in medical oncology at the Institut Jules Bordet.

Professor Klastersky was an intern and resident at the University Hospitals of the Université Libre de Bruxelles between 1962 and 1965, where he gained his MD (Docteur en Médecine, Chirurgie et Accouchements).From 1967 to 1968, he was Chief-Resident at Boston City Hospital and then a Research Fellowand Assistant in Medicine at Thorndike Memorial Laboratory Harvard Medical School. He became Chief of the Section of Infectious Diseases at the Institut Jules Bordet in 1970, before taking up the position of Head of the Department of Medicine in 1977.

Professor Klastersky was a founder member of the European Lung Cancer Working Party and has been his President since 1978 until 2003. He was President (and founder member) of the International EORTC Antimicrobial Therapy Project Group between 1979 and 1987 and the Group’s Secretary General from 1987 to 2000. He was President (and founder member) of the Multinational Association for Supportive Care in Cancer (MASCC) from 1990 to 2000.

He is Visiting Professor of Medical Oncology at the Charles University in Prague, since 1994.

Professor Klastersky is a member of the American Society of Clinical Oncology, the American Association of Cancer Research, the European Society of Medical Oncology, the American Society of Microbiology, the Infectious Diseases Society of America, the International Association for the Study of Lung Cancer, the “Royale Académie de Médecine” of Belgium and various other international and national medical and/or oncological societies.

Professor Klastersky is the author of over 500 original articles, nearly 400 review articles and 17 scientific books.

He is the Editor of Current Opinion in Oncology.

All rights reserved © 2018
HQ/ONCO/18/0003 | Preparation date: October 2018
Reporting of suspected adverse events is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
To ensure correct adverse event reporting, healthcare professionals are encouraged to use the appropriate website for their national authority.